Low muscle mass ups risk of recurrence, death after radical prostatectomy in prostate cancer patients
There appears to be an association between low muscle mass and increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index (BMI), suggests a recent study.
The 10-year distant metastasis-free survival rates in the lowest, second, third and highest psoas muscle index quartiles were 72.5 percent, 83.8 percent, 92.3 percent and 93.7 percent (p<0.001), respectively, while the 10-year cancer-specific survival rates were 85.7 percent, 92.1 percent, 96.8 percent and 97.6 percent. The corresponding 10-year overall survival rates were 74.5 percent, 79.6 percent, 89.8 percent and 90.6 percent (p<0.001 for each).
Moreover, the psoas muscle index was positively associated with BMI, serum concentrations of IGFBP-3 and bioavailable testosterone, and inversely associated with patient age, serum SHBG concentration and the neutrophil-to-lymphocyte ratio. Multivariable analysis revealed the association of the psoas muscle index with increased risks of biochemical recurrence, distant metastasis, and cancer-specific and overall mortality.
“Large-scale prospective studies are warranted [to confirm these findings],” the authors said.
This study was a retrospective examination of the association between muscle mass and survival following radical prostatectomy in patients with prostate cancer. Records of 2,042 patients who underwent radical prostatectomy of prostate cancer between 1998 and 2013 were reviewed. The psoas muscle index was measured on preoperative computerized tomography images to assess muscle mass.
Muscle mass has been associated with survival in patients with various types of solid tumours, according to the authors, and this investigation further elucidates the relationship between muscle mass and survival in patients with prostate cancer.